: Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022 #FinanceUSA #StockMarketNEWS Merck and partner privately held Ridgeback Biotherapeutics said Tuesday

@stockMarketNEWS Tue 18 Jan, 2022

Posted in: #FinanceUSA #StockMarketNEWS

Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022 #FinanceUSA #StockMarketNEWS
Merck and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children's Fund, or Unicef, to provide it with up to 3 million doses of their COVID-19 antiviral molnupiravir in the first half of 2022. The doses will be distributed in more than 100 low and middle-income countries following regulatory authorizations. The treatment has already been authorized in more than 10 countries, including the U.S., UK, Japan and Taiwan. Merck shares were not yet active premarket, but have gained 2.4% in the last 12 months, while the S&P 500 has gained 24%.

Munafa USA Munafa India Munafa NSE

Report

Login to post a comment!